Featured Editorial

71. Faster, Easier, and More Anxiety-Inducing: Are DHTs Harming Patients' Mental Health? 2/2/2023

    Digital health technology (DHT) filled the communication gap created by physical distance during the pandemic, but have we created more space between participant and provider as we increasingly introduce and rely upon technology?

72. The 3 Stages Of Decentralized Trial Maturity 2/1/2023

    Decentralized clinical trials (DCTs) offer clear benefits to patients and the overall success of the trial, but it can be difficult to know how to address this challenge. This three-stage framework approach will enable you to assess your organization’s current clinical trial innovation maturity and build a plan from there.

73. The 5Vs Of Collecting Clinical Data 1/26/2023

    Not all data is created equal. Our data strategies need to be commensurate with the risks, complexity, and value of the data collected. If the true value of data is to be realized, it must be collected and captured in accordance with the five “V” dimensions: volume, variety, velocity, veracity, and value.

74. How BMS Uses AI To Improve Study Design And Reduce Costs 1/19/2023

    In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.

75. Clinical Sites Are Optimistic, Despite Growing Challenges 1/17/2023

    The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.

76. How Can Clinical Research Better Navigate Healthcare Deserts? 1/17/2023

    Large swaths of the U.S. remain healthcare deserts, where access to clinical sites, pharmacies, and hospitals is limited. This contributes to underrepresentation in clinical research. What are the roles of technology and community outreach, and what are some current industry efforts to address it?

77. The Long-Term Impact Of COVID-19 On Clinical Trials: Part 1 1/11/2023

    Pandemics provide a massive pressure-test of healthcare systems, allowing us to isolate what works well and what merits improvement. The COVID-19 pandemic is going to create a “new normal” regarding resetting the equilibrium in a variety of policies, procedures, and processes. In Part 1, we examine five factors that more directly impact the clinical trial process and patients.

78. 2 Key Areas To Leverage AI/ML For More Successful Clinical Trials 1/3/2023

    Artificial intelligence (AI) and machine learning (ML) can be used to minimize errors in clinical trial participant management and streamline data management. However, realizing the full potential of this technology will require overcoming issues such as data quality/access, transparency of development and validation processes, and potential data bias.

79. Two Straightforward Ways To Improve DE&I In Clinical Trials 12/27/2022

    We don’t have to wait for federal guidance, additional DHT, or new innovations. We have the tools to begin to address the lack of trust and limited data and incorporate them into diversity plans for clinical trials today. Here's how.

80. How One Pharma Company Is Embracing Digital Technologies 12/21/2022

    The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.